The safety, tolerability and efficacy of the combination of fluorouracil (5FU) and the monoclonal VEGF-A antibody bevacizumab plus anakinra was already evaluated in a single-arm phase II study in patients with refractory metastatic colorectal cancer (IRAFU). The gene discussed is VEGFA; the disease is metastatic colorectal cancer.